These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35686260)

  • 1. A Case of Bullous Pemphigoid Associated With Nivolumab Therapy.
    Gotera N; Weilg P; Heleno C; Ferrari-Gabilondo N
    Cureus; 2022 May; 14(5):e24804. PubMed ID: 35686260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.
    Huynh LM; Bonebrake BT; DiMaio DJ; Baine MJ; Teply BA
    Medicine (Baltimore); 2021 Dec; 100(49):e28199. PubMed ID: 34889301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
    Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
    Front Immunol; 2022; 13():984132. PubMed ID: 36189265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid.
    Liu M; Yuan M; Sun W; Li Z; Zhou X; Wang C
    Invest New Drugs; 2023 Dec; 41(6):802-807. PubMed ID: 37773473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab.
    Olsen E; Svoboda SA; Saikaly SK; Missall TA; Motaparthi K
    Cureus; 2023 Aug; 15(8):e43230. PubMed ID: 37692698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab.
    Bruni M; Moar A; Schena D; Girolomoni G
    Dermatol Online J; 2022 Mar; 28(2):. PubMed ID: 35670683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interventions for bullous pemphigoid.
    Singh S; Kirtschig G; Anchan VN; Chi CC; Taghipour K; Boyle RJ; Murrell DF
    Cochrane Database Syst Rev; 2023 Aug; 8(8):CD002292. PubMed ID: 37572360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Rare Case of Bullous Pemphigoid Secondary to Checkpoint Inhibitor Immunotherapy: A Tense Situation.
    Wesolow JT; Jalali S; Clark LD
    Cureus; 2021 Jul; 13(7):e16169. PubMed ID: 34367779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report.
    Alshammari F; Abuzied Y; Korairi A; Alajlan M; Alzomia M; AlSheef M
    Ann Med Surg (Lond); 2022 Mar; 75():103420. PubMed ID: 35251600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
    Aggarwal P
    Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
    [No Abstract]   [Full Text] [Related]  

  • 11. Concomitant nivolumab-associated Grover disease and bullous pemphigoid in a patient with metastatic renal cell carcinoma.
    Khazaeli M; Grover R; Pei S
    J Cutan Pathol; 2023 Jun; 50(6):520-523. PubMed ID: 36601731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors.
    Mazumder A; Darji K; Smith K; Guo M
    BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.
    Klepper EM; Robinson HN
    Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case report of bullous pemphigoid associated with a melanoma and review of the literature.
    Amber KT; Panganiban CM; Korta D; Feraudy S; Kelly KM; Grando SA
    Melanoma Res; 2017 Feb; 27(1):65-67. PubMed ID: 27759577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Case of Drug-Induced Bullous Pemphigoid With an Isomorphic Response and Updated Review of Koebnerization in Bullous Diseases.
    Ambur AB; Nathoo R; Saeed S
    Cureus; 2021 Dec; 13(12):e20647. PubMed ID: 35106205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.
    Lopez AT; Geskin L
    Oncologist; 2018 Oct; 23(10):1119-1126. PubMed ID: 30018132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.
    Cosimati A; Rossi L; Didona D; Forcella C; Didona B
    J Oncol Pharm Pract; 2021 Apr; 27(3):727-733. PubMed ID: 32772795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Patient Develops Bullous Rash After Receiving the Second Dose of COVID-19 Vaccine.
    Nida SS; Tobon GJ; Wilson M; Chauhan K
    Cureus; 2022 Sep; 14(9):e29786. PubMed ID: 36340561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
    Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
    Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab-induced localized genital bullous pemphigoid in a 60-year-old male.
    Alvarado SM; Weston G; Murphy MJ; Stewart CL
    J Cutan Pathol; 2022 May; 49(5):468-471. PubMed ID: 34881446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.